These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 9933352

  • 1. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.
    Booij J, Tissingh G, Winogrodzka A, van Royen EA.
    Eur J Nucl Med; 1999 Feb; 26(2):171-82. PubMed ID: 9933352
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
    Frey KA.
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):715-7. PubMed ID: 11976814
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean?
    Kim Y, Kim JM, Kim JW, Yoo CI, Lee CR, Lee JH, Kim HK, Yang SO, Chung HK, Lee DS, Jeon B.
    Mov Disord; 2002 May; 17(3):568-75. PubMed ID: 12112209
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand.
    Løkkegaard A, Werdelin LM, Friberg L.
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1623-9. PubMed ID: 12458397
    [Abstract] [Full Text] [Related]

  • 8. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E, Verhoeff NF, Speelman JD, Wolters EC, Kuiper MA, Janssen AG.
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [Abstract] [Full Text] [Related]

  • 9. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D.
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [Abstract] [Full Text] [Related]

  • 10. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M.
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [Abstract] [Full Text] [Related]

  • 11. [123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls.
    Tissingh G, Bergmans P, Booij J, Winogrodzka A, Stoof JC, Wolters EC, Van Royen EA.
    Eur J Nucl Med; 1997 Sep; 24(9):1171-4. PubMed ID: 9283113
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
    Jeon B, Kim JM, Jeong JM, Kim KM, Chang YS, Lee DS, Lee MC.
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Is functional imaging useful in the clinical evaluation of Parkinson's disease?].
    Remy P.
    Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S57-61. PubMed ID: 12773889
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
    Chalon S, Emond P, Bodard S, Vilar MP, Thiercelin C, Besnard JC, Guilloteau D.
    Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010
    [Abstract] [Full Text] [Related]

  • 20. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.